Daniele Santi1, Elisa Giannetta2, Andrea M Isidori2, Cristiana Vitale2, Antonio Aversa2, Manuela Simoni3. 1. Unit of EndocrinologyDepartment of Biomedical Metabolic and Neural Sciences. University of Modena and Reggio Emilia, ItalyAzienda USL of ModenaItalySapienza University of RomeDepartment of Experimental MedicineDepartment of Medical SciencesIRCSS San Raffaele, Rome, Italy Unit of EndocrinologyDepartment of Biomedical Metabolic and Neural Sciences. University of Modena and Reggio Emilia, ItalyAzienda USL of ModenaItalySapienza University of RomeDepartment of Experimental MedicineDepartment of Medical SciencesIRCSS San Raffaele, Rome, Italy. 2. Unit of EndocrinologyDepartment of Biomedical Metabolic and Neural Sciences. University of Modena and Reggio Emilia, ItalyAzienda USL of ModenaItalySapienza University of RomeDepartment of Experimental MedicineDepartment of Medical SciencesIRCSS San Raffaele, Rome, Italy. 3. Unit of EndocrinologyDepartment of Biomedical Metabolic and Neural Sciences. University of Modena and Reggio Emilia, ItalyAzienda USL of ModenaItalySapienza University of RomeDepartment of Experimental MedicineDepartment of Medical SciencesIRCSS San Raffaele, Rome, Italy Unit of EndocrinologyDepartment of Biomedical Metabolic and Neural Sciences. University of Modena and Reggio Emilia, ItalyAzienda USL of ModenaItalySapienza University of RomeDepartment of Experimental MedicineDepartment of Medical SciencesIRCSS San Raffaele, Rome, Italy manuela.simoni@unimore.it.
Abstract
OBJECTIVE: Diabetes mellitus (DM) is associated with endothelial dysfunction, reducing nitric oxide-dependent vasodilation, and increasing production of pro-inflammatory factors, leading to an increased risk of long-term cardiovascular disease. As the effects of phosphodiesterase 5 inhibitors (PDE5i) on endothelial function have not been systematically investigated, we conducted a meta-analysis of available randomized clinical trials (RCTs). DESIGN: A thorough search of the literature was carried out. Relevant studies were considered according to RCT study design, enrollment of men with type 2 DM, chronic administration of PDE5i, and evaluation of endothelial function through both hemodynamic and endothelial inflammation-related parameters. RESULTS: Fifteen studies fulfilled the eligibility criteria but only six RCTs met the inclusion criteria and were analyzed for 476 diabetic men, 239 randomized to Sildenafil, and 237 to placebo respectively. Four RCTs evaluated flow-mediated dilation (FMD), demonstrating a weighted mean increase of 2.19% (95% CI 0.48 to 3.90). This result showed a high heterogeneity (I(2): 98%). Thus, a further sub-group meta-analysis was performed and this analysis confirmed a significant, Sildenafil-related FMD improvement. Sildenafil improved endothelin 1 and high sensitivity C-reactive protein by ∼-0.94 pg/ml and -0.36 mg/l, respectively, not reaching statistical significance (P=0.69 and P=0.22 respectively). Finally, Sildenafil administration significantly reduced serum levels of interleukin 6 (IL6, -0.82 pg/ml; 95% CI -1.58 to -0.07). CONCLUSION: This meta-analysis suggests a beneficial effect of chronic PDE5i administration on endothelial function. Chronic Sildenafil administration seems to improve hemodynamic (FMD) and serum pro-inflammatory makers (IL6) in diabetic men. Larger studies are needed to confirm the effects of chronic PDE5i on endothelial function.
OBJECTIVE:Diabetes mellitus (DM) is associated with endothelial dysfunction, reducing nitric oxide-dependent vasodilation, and increasing production of pro-inflammatory factors, leading to an increased risk of long-term cardiovascular disease. As the effects of phosphodiesterase 5 inhibitors (PDE5i) on endothelial function have not been systematically investigated, we conducted a meta-analysis of available randomized clinical trials (RCTs). DESIGN: A thorough search of the literature was carried out. Relevant studies were considered according to RCT study design, enrollment of men with type 2 DM, chronic administration of PDE5i, and evaluation of endothelial function through both hemodynamic and endothelial inflammation-related parameters. RESULTS: Fifteen studies fulfilled the eligibility criteria but only six RCTs met the inclusion criteria and were analyzed for 476 diabeticmen, 239 randomized to Sildenafil, and 237 to placebo respectively. Four RCTs evaluated flow-mediated dilation (FMD), demonstrating a weighted mean increase of 2.19% (95% CI 0.48 to 3.90). This result showed a high heterogeneity (I(2): 98%). Thus, a further sub-group meta-analysis was performed and this analysis confirmed a significant, Sildenafil-related FMD improvement. Sildenafil improved endothelin 1 and high sensitivity C-reactive protein by ∼-0.94 pg/ml and -0.36 mg/l, respectively, not reaching statistical significance (P=0.69 and P=0.22 respectively). Finally, Sildenafil administration significantly reduced serum levels of interleukin 6 (IL6, -0.82 pg/ml; 95% CI -1.58 to -0.07). CONCLUSION: This meta-analysis suggests a beneficial effect of chronic PDE5i administration on endothelial function. Chronic Sildenafil administration seems to improve hemodynamic (FMD) and serum pro-inflammatory makers (IL6) in diabeticmen. Larger studies are needed to confirm the effects of chronic PDE5i on endothelial function.
Authors: Antonio Aversa; Simona Fittipaldi; Davide Francomano; Viviana M Bimonte; Emanuela A Greco; Clara Crescioli; Luigi Di Luigi; Andrea Lenzi; Silvia Migliaccio Journal: Endocrine Date: 2017-01-30 Impact factor: 3.633
Authors: Giuseppe Defeudis; Rossella Mazzilli; Marta Tenuta; Giovanni Rossini; Virginia Zamponi; Soraya Olana; Antongiulio Faggiano; Paolo Pozzilli; Andrea M Isidori; Daniele Gianfrilli Journal: Diabetes Metab Res Rev Date: 2021-09-21 Impact factor: 8.128
Authors: Andreas Daiber; Sebastian Steven; Alina Weber; Vladimir V Shuvaev; Vladimir R Muzykantov; Ismail Laher; Huige Li; Santiago Lamas; Thomas Münzel Journal: Br J Pharmacol Date: 2016-07-04 Impact factor: 8.739
Authors: Baris Afsar; Alberto Ortiz; Adrian Covic; Abduzhappar Gaipov; Tarik Esen; David Goldsmith; Mehmet Kanbay Journal: Int Urol Nephrol Date: 2015-08-05 Impact factor: 2.370
Authors: Mary Anna Venneri; Elisa Giannetta; Giuseppe Panio; Rita De Gaetano; Daniele Gianfrilli; Riccardo Pofi; Silvia Masciarelli; Francesco Fazi; Manuela Pellegrini; Andrea Lenzi; Fabio Naro; Andrea M Isidori Journal: PLoS One Date: 2015-05-11 Impact factor: 3.240